Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 88

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 88
---
cin administration after the bacterial challenge 
 vs. free mupirocin administration. Survival of mice in response to increasing doses of Nano-Mupirocin.                           |

<div align='center'>54</div>

Figure 7. Appearance of a typical Nano-Mupirocin-treated mouse (A) vs. an untreated one (B) 24 h after bacterial challenge.

Figure 8: Plasma profile of mupirocin after IV administration of 40 mg/kg free vs. Nano-Mupirocin.

Reference: Ahuva Cern, Ayelet Michael-Gayego, Yaelle Bavli, Erez Korena, Amiram Goldblum, Allon E. Moses, Yan Q. Xiong and Yechezkel Barenholz* Nano-Mupirocin: enabling the parenteral activity of mupirocin DOI 10.1515/ejnm-2016-0006

<div align='center'>55</div>

| 5. | Biodistribution and Pharmacokinetics |

PK studies in mice (n=4 per time point) showed
that Nano-Mupirocin had a terminal half-life of 262 minutes vs. 5.3 minutes for free mupirocin. The area under the curve (AUC) was ~97-fold
higher for Nano-Mupirocin, confirming sustained systemic exposure. Biodistribution studies showed accumulation in infected organs and
in mucosal secretions (e.g., vaginal fluid), maintaining drug concentrations well above the MIC₉₀ for >24h

Figure 9: Vaginal Smear Fluorescence. Fluorescence microscopy of vaginal smears. (A,B) are overlays of Differential interference contrast (DIC) and Fluorescent Light. (A), un-treated mice; (B), mice treated with LRPE-Nano-mupirocin; (C,D), smears of LRPE-Nano-mupirocin observed under fluorescent light. Scale bar = 50 μm.

Figure 10: Mupirocin in Vaginal Secretions. Mupirocin concentration (free (non-liposomal) plus liposomal) in vaginal secretions (ng/g) and plasma (ng/mL) following IP administration of Nano-mupirocin 50 mg/kg (mean ± SE). (n = 5 for swab samples and n = 4 for plasma samples).

<div align='center'>56</div>

Substantial pre-clinical research of the novel